

Sequential and AMILI secure \$1.8M UK-Singapore R&D project to advance gut-skin microbiome science

13 February 2025 | News

For evaluating inflammatory skin disorders such as atopic dermatitis and psoriasis



Sequential Skin, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, have been awarded the prestigious UK-Singapore Collaborative R&D Grant.

The \$1.8 million project, supported by Innovate UK and Enterprise SG, will make significant strides in characterising the interplay between the skin and gut microbiome, offering a groundbreaking approach to evaluating inflammatory skin disorders (ISDs) such as atopic dermatitis and psoriasis.

Sequential has built a database of over 25,000 clinical skin microbiome samples and has pioneered the world's early skin microbiome at-home tests that were made commercially available in 2019. The previous recipient of an Innovate UK Smart Grant, with labs in US, Europe and Asia, Sequential is currently working with over 80 personal care and pharmaceutical companies innovating in the skin microbiome field.

AMILI, headquartered in Singapore, has been at the forefront of gut microbiome research. Since AMILI founders performed the first gut microbiome transplants in the region in 2014, AMILI has focused on developing and deeply analysing Asia's largest multi-ethnic gut microbiome database to map the relationships and mechanistic pathways between changes in the gut microbiome and health conditions.

This funding allows both organisations to accelerate their efforts in developing targeted, microbiome-driven interventions.